Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFM13 + Pembrolizumab in R/R Hodgkin Lymphoma
NCT02665650Phase 1Completed
- Sponsor
- Affimed
- Start
- May 2016
- Primary completion
- Jan 2019
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of acimtamig in Hodgkin lymphoma (HL), sponsored by Affimed. Primary endpoint: Dose Limiting Toxicity at 9 months. Started May 2016; status: completed.
02
Drugs
acimtamig
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02665650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02665650.